DK1017379T3 - Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf - Google Patents

Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf Download PDF

Info

Publication number: DK1017379T3
Authority: DK; Denmark
Prior art keywords: compound; esters; hydroxybutyrate; acetoacetate; alcohols
Prior art date: 1997-03-17

Application number

DK98911664.5T

Other languages

English (en)

Inventor

Richard L Veech

Original Assignee

Btg Int Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-17

Filing date

1998-03-17

Publication date

2015-02-16

1998-03-17 Application filed by Btg Int Ltd filed Critical Btg Int Ltd

2015-02-16 Application granted granted Critical

2015-02-16 Publication of DK1017379T3 publication Critical patent/DK1017379T3/da

Links

239000002243 precursor Substances 0.000 title claims description 20
-1 ketone compounds Chemical class 0.000 title claims description 14
239000000203 mixture Substances 0.000 title description 29
230000001225 therapeutic effect Effects 0.000 title description 3
WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 claims description 50
150000002148 esters Chemical class 0.000 claims description 34
208000024827 Alzheimer disease Diseases 0.000 claims description 29
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 29
239000008103 glucose Substances 0.000 claims description 29
238000011282 treatment Methods 0.000 claims description 28
150000001875 compounds Chemical class 0.000 claims description 24
229920000642 polymer Polymers 0.000 claims description 22
108090000623 proteins and genes Proteins 0.000 claims description 19
230000002503 metabolic effect Effects 0.000 claims description 18
150000001298 alcohols Chemical class 0.000 claims description 17
102000004169 proteins and genes Human genes 0.000 claims description 15
230000036765 blood level Effects 0.000 claims description 10
208000015122 neurodegenerative disease Diseases 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 8
150000003839 salts Chemical class 0.000 claims description 8
WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 claims description 7
150000003626 triacylglycerols Chemical class 0.000 claims description 7
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 6
206010012289 Dementia Diseases 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
208000026139 Memory disease Diseases 0.000 claims description 6
230000002068 genetic effect Effects 0.000 claims description 6
208000000044 Amnesia Diseases 0.000 claims description 5
230000006984 memory degeneration Effects 0.000 claims description 5
208000023060 memory loss Diseases 0.000 claims description 5
206010003694 Atrophy Diseases 0.000 claims description 4
230000005856 abnormality Effects 0.000 claims description 4
230000032683 aging Effects 0.000 claims description 4
230000037444 atrophy Effects 0.000 claims description 4
201000010374 Down Syndrome Diseases 0.000 claims description 3
208000027089 Parkinsonian disease Diseases 0.000 claims description 3
206010034010 Parkinsonism Diseases 0.000 claims description 3
206010044688 Trisomy 21 Diseases 0.000 claims description 3
230000002887 neurotoxic effect Effects 0.000 claims description 3
208000011990 Corticobasal Degeneration Diseases 0.000 claims description 2
201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
206010039966 Senile dementia Diseases 0.000 claims description 2
201000004810 Vascular dementia Diseases 0.000 claims description 2
210000004558 lewy body Anatomy 0.000 claims description 2
201000006938 muscular dystrophy Diseases 0.000 claims description 2
206010028417 myasthenia gravis Diseases 0.000 claims description 2
231100000189 neurotoxic Toxicity 0.000 claims description 2
201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
101000795849 Calliactis parasitica Delta-hormotoxin-Cpt1b Proteins 0.000 claims 1
125000005233 alkylalcohol group Chemical group 0.000 claims 1
150000002576 ketones Chemical class 0.000 description 97
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
210000004369 blood Anatomy 0.000 description 48
239000008280 blood Substances 0.000 description 48
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 43
102000004877 Insulin Human genes 0.000 description 32
108090001061 Insulin Proteins 0.000 description 32
229940125396 insulin Drugs 0.000 description 32
210000004556 brain Anatomy 0.000 description 28
235000005911 diet Nutrition 0.000 description 28
210000004027 cell Anatomy 0.000 description 26
230000037213 diet Effects 0.000 description 26
230000000694 effects Effects 0.000 description 24
WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 23
230000001965 increasing effect Effects 0.000 description 21
210000004185 liver Anatomy 0.000 description 21
238000004519 manufacturing process Methods 0.000 description 18
230000002438 mitochondrial effect Effects 0.000 description 18
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 16
230000007423 decrease Effects 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 14
150000001720 carbohydrates Chemical class 0.000 description 14
235000014633 carbohydrates Nutrition 0.000 description 14
150000002632 lipids Chemical class 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
235000018102 proteins Nutrition 0.000 description 13
238000003786 synthesis reaction Methods 0.000 description 12
241000282414 Homo sapiens Species 0.000 description 11
235000021588 free fatty acids Nutrition 0.000 description 11
239000000463 material Substances 0.000 description 11
238000000034 method Methods 0.000 description 11
239000000758 substrate Substances 0.000 description 11
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 10
229960004373 acetylcholine Drugs 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
230000007812 deficiency Effects 0.000 description 9
206010012601 diabetes mellitus Diseases 0.000 description 9
201000010099 disease Diseases 0.000 description 9
210000002216 heart Anatomy 0.000 description 9
235000020887 ketogenic diet Nutrition 0.000 description 9
239000000047 product Substances 0.000 description 9
235000000346 sugar Nutrition 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
241000700159 Rattus Species 0.000 description 8
230000003247 decreasing effect Effects 0.000 description 8
230000006870 function Effects 0.000 description 8
230000000971 hippocampal effect Effects 0.000 description 8
210000002569 neuron Anatomy 0.000 description 8
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 8
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 8
239000011734 sodium Substances 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 7
239000002253 acid Substances 0.000 description 7
230000030833 cell death Effects 0.000 description 7
230000002440 hepatic effect Effects 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
239000002609 medium Substances 0.000 description 7
239000000178 monomer Substances 0.000 description 7
230000004102 tricarboxylic acid cycle Effects 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000009825 accumulation Methods 0.000 description 6
230000002490 cerebral effect Effects 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
230000034994 death Effects 0.000 description 6
230000037406 food intake Effects 0.000 description 6
230000015654 memory Effects 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
230000004770 neurodegeneration Effects 0.000 description 6
230000001575 pathological effect Effects 0.000 description 6
229920000728 polyester Polymers 0.000 description 6
230000002035 prolonged effect Effects 0.000 description 6
230000009467 reduction Effects 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
230000032258 transport Effects 0.000 description 6
208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
208000037259 Amyloid Plaque Diseases 0.000 description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
101710088194 Dehydrogenase Proteins 0.000 description 5
BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 5
150000004729 acetoacetic acid derivatives Chemical class 0.000 description 5
230000009471 action Effects 0.000 description 5
210000000349 chromosome Anatomy 0.000 description 5
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 5
230000001086 cytosolic effect Effects 0.000 description 5
230000007547 defect Effects 0.000 description 5
230000006735 deficit Effects 0.000 description 5
235000019197 fats Nutrition 0.000 description 5
230000034659 glycolysis Effects 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
230000006872 improvement Effects 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
210000005036 nerve Anatomy 0.000 description 5
235000016709 nutrition Nutrition 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
108010026424 tau Proteins Proteins 0.000 description 5
102000013498 tau Proteins Human genes 0.000 description 5
PUPZLCDOIYMWBV-SCSAIBSYSA-N (R)-butane-1,3-diol Chemical compound C[C@@H](O)CCO PUPZLCDOIYMWBV-SCSAIBSYSA-N 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
108091052347 Glucose transporter family Proteins 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229910001424 calcium ion Inorganic materials 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
210000000805 cytoplasm Anatomy 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
229960003692 gamma aminobutyric acid Drugs 0.000 description 4
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
210000001320 hippocampus Anatomy 0.000 description 4
230000002218 hypoglycaemic effect Effects 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
235000015424 sodium Nutrition 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
102100022704 Amyloid-beta precursor protein Human genes 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical group CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
108010058699 Choline O-acetyltransferase Proteins 0.000 description 3
102100023460 Choline O-acetyltransferase Human genes 0.000 description 3
102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010021000 Hypoglycaemic coma Diseases 0.000 description 3
102000002568 Multienzyme Complexes Human genes 0.000 description 3
108010093369 Multienzyme Complexes Proteins 0.000 description 3
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 3
229930182555 Penicillin Natural products 0.000 description 3
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
125000002339 acetoacetyl group Chemical group O=C([*])C([H])([H])C(=O)C([H])([H])[H] 0.000 description 3
OJFDKHTZOUZBOS-CITAKDKDSA-N acetoacetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 OJFDKHTZOUZBOS-CITAKDKDSA-N 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
210000003050 axon Anatomy 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000012937 correction Methods 0.000 description 3
230000002950 deficient Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
206010015037 epilepsy Diseases 0.000 description 3
238000009472 formulation Methods 0.000 description 3
235000003642 hunger Nutrition 0.000 description 3
238000011534 incubation Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
210000003470 mitochondria Anatomy 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
229940049954 penicillin Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000037351 starvation Effects 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
150000008163 sugars Chemical class 0.000 description 3
238000012360 testing method Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
208000019553 vascular disease Diseases 0.000 description 3
JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 2
WHBMMWSBFZVSSR-VKHMYHEASA-N (S)-3-hydroxybutyric acid Chemical compound C[C@H](O)CC(O)=O WHBMMWSBFZVSSR-VKHMYHEASA-N 0.000 description 2
CSXINIGTBHLAAV-UHFFFAOYSA-N 5,6,7-trihydroxyheptane-2,4-dione Chemical compound CC(=O)CC(=O)C(O)C(O)CO CSXINIGTBHLAAV-UHFFFAOYSA-N 0.000 description 2
230000002407 ATP formation Effects 0.000 description 2
102100029470 Apolipoprotein E Human genes 0.000 description 2
101710095339 Apolipoprotein E Proteins 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102100022768 D-beta-hydroxybutyrate dehydrogenase, mitochondrial Human genes 0.000 description 2
208000001654 Drug Resistant Epilepsy Diseases 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108090000371 Esterases Proteins 0.000 description 2
208000004930 Fatty Liver Diseases 0.000 description 2
108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
206010019708 Hepatic steatosis Diseases 0.000 description 2
208000013016 Hypoglycemia Diseases 0.000 description 2
206010022489 Insulin Resistance Diseases 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
108010036933 Presenilin-1 Proteins 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical group CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000005904 alkaline hydrolysis reaction Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
210000004958 brain cell Anatomy 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
235000019577 caloric intake Nutrition 0.000 description 2
229960001231 choline Drugs 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
230000001713 cholinergic effect Effects 0.000 description 2
230000004087 circulation Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000030609 dephosphorylation Effects 0.000 description 2
238000006209 dephosphorylation reaction Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000000378 dietary effect Effects 0.000 description 2
WASQWSOJHCZDFK-UHFFFAOYSA-N diketene Chemical compound C=C1CC(=O)O1 WASQWSOJHCZDFK-UHFFFAOYSA-N 0.000 description 2
208000010706 fatty liver disease Diseases 0.000 description 2
235000013305 food Nutrition 0.000 description 2
235000014105 formulated food Nutrition 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000000446 fuel Substances 0.000 description 2
230000004116 glycogenolysis Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002064 heart cell Anatomy 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
201000001421 hyperglycemia Diseases 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002361 ketogenic effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
235000020855 low-carbohydrate diet Nutrition 0.000 description 2
235000013310 margarine Nutrition 0.000 description 2
239000003264 margarine Substances 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
230000006386 memory function Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229950006238 nadide Drugs 0.000 description 2
230000003955 neuronal function Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
235000021590 normal diet Nutrition 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
238000012261 overproduction Methods 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
231100000915 pathological change Toxicity 0.000 description 2
230000036285 pathological change Effects 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000000843 powder Substances 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
230000004044 response Effects 0.000 description 2
229940082569 selenite Drugs 0.000 description 2
MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
231100000240 steatosis hepatitis Toxicity 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
230000002889 sympathetic effect Effects 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
229940034208 thyroxine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 description 1
102000005460 3-oxoacid CoA-transferase Human genes 0.000 description 1
108020002872 3-oxoacid CoA-transferase Proteins 0.000 description 1
OCTMEDVZTZDLFJ-UHFFFAOYSA-N 3-oxobutanoyl 3-hydroxybutanoate Chemical compound CC(O)CC(=O)OC(=O)CC(C)=O OCTMEDVZTZDLFJ-UHFFFAOYSA-N 0.000 description 1
ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
102000004146 ATP citrate synthases Human genes 0.000 description 1
108090000662 ATP citrate synthases Proteins 0.000 description 1
101150024971 ATP4 gene Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
206010048998 Acute phase reaction Diseases 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
206010003628 Atonic seizures Diseases 0.000 description 1
239000012583 B-27 Supplement Substances 0.000 description 1
241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
206010048962 Brain oedema Diseases 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
208000032170 Congenital Abnormalities Diseases 0.000 description 1
241000252867 Cupriavidus metallidurans Species 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102000042092 Glucose transporter family Human genes 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
108010001483 Glycogen Synthase Proteins 0.000 description 1
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
108010072039 Histidine kinase Proteins 0.000 description 1
101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
206010048803 Hypoglycaemic seizure Diseases 0.000 description 1
208000009773 Insulin Coma Diseases 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
208000007976 Ketosis Diseases 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
102000017298 Monocarboxylate transporters Human genes 0.000 description 1
108050005244 Monocarboxylate transporters Proteins 0.000 description 1
102000000562 Monocarboxylic Acid Transporters Human genes 0.000 description 1
108010041817 Monocarboxylic Acid Transporters Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
102000000728 Nerve growth factor-like Human genes 0.000 description 1
108050008149 Nerve growth factor-like Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
101100436871 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) atp-3 gene Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
208000016222 Pancreatic disease Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000012412 Presenilin-1 Human genes 0.000 description 1
108010050254 Presenilins Proteins 0.000 description 1
208000024777 Prion disease Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
102000005569 Protein Phosphatase 1 Human genes 0.000 description 1
108010059000 Protein Phosphatase 1 Proteins 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
101150110386 SLC2A4 gene Proteins 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
235000021536 Sugar beet Nutrition 0.000 description 1
241000282887 Suidae Species 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
102000003673 Symporters Human genes 0.000 description 1
108090000088 Symporters Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
102000013127 Vimentin Human genes 0.000 description 1
108010065472 Vimentin Proteins 0.000 description 1
208000010399 Wasting Syndrome Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
235000019631 acid taste sensations Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
206010000891 acute myocardial infarction Diseases 0.000 description 1
230000004658 acute-phase response Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
230000002424 anti-apoptotic effect Effects 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229920000704 biodegradable plastic Polymers 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
230000005978 brain dysfunction Effects 0.000 description 1
208000006752 brain edema Diseases 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
235000008429 bread Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000021074 carbohydrate intake Nutrition 0.000 description 1
229950005499 carbon tetrachloride Drugs 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
108010079058 casein hydrolysate Proteins 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
210000001787 dendrite Anatomy 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
230000037149 energy metabolism Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000001037 epileptic effect Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000003810 ethyl acetate extraction Methods 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
230000004136 fatty acid synthesis Effects 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
238000003304 gavage Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000009395 genetic defect Effects 0.000 description 1
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
230000002414 glycolytic effect Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000004295 hippocampal neuron Anatomy 0.000 description 1
235000006486 human diet Nutrition 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000006951 hyperphosphorylation Effects 0.000 description 1
208000006575 hypertriglyceridemia Diseases 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229910001410 inorganic ion Inorganic materials 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000004140 ketosis Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
235000020888 liquid diet Nutrition 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
244000005700 microbiome Species 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
230000002151 myoclonic effect Effects 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
208000015015 neurological dysfunction Diseases 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000011368 organic material Substances 0.000 description 1
KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
235000015927 pasta Nutrition 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
235000007686 potassium Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
235000012015 potatoes Nutrition 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
235000011962 puddings Nutrition 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
235000009643 reducing diet Nutrition 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
238000009738 saturating Methods 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002813 septal nuclei Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
MOSCXNXKSOHVSQ-UHFFFAOYSA-M sodium;2-hydroxybutanoate Chemical compound [Na+].CCC(O)C([O-])=O MOSCXNXKSOHVSQ-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
210000003523 substantia nigra Anatomy 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
229940064707 sympathomimetics Drugs 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
235000019630 tart taste sensations Nutrition 0.000 description 1
230000009967 tasteless effect Effects 0.000 description 1
108010061506 tau-protein kinase Proteins 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
210000003478 temporal lobe Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
108091007466 transmembrane glycoproteins Proteins 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000013638 trimer Substances 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000035899 viability Effects 0.000 description 1
210000005048 vimentin Anatomy 0.000 description 1
239000000052 vinegar Substances 0.000 description 1
235000021419 vinegar Nutrition 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1
235000013618 yogurt Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
- C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
- C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Polymers & Plastics (AREA)
Hematology (AREA)
Mycology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Polyesters Or Polycarbonates (AREA)
Biological Depolymerization Polymers (AREA)

DK98911664.5T 1997-03-17 1998-03-17 Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf DK1017379T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US4085897P	1997-03-17	1997-03-17
PCT/US1998/005072 WO1998041201A1 (en)	1997-03-17	1998-03-17	Therapeutic compositions

Publications (1)

Publication Number	Publication Date
DK1017379T3 true DK1017379T3 (da)	2015-02-16

Family

ID=21913362

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK98911664.5T DK1017379T3 (da)	1997-03-17	1998-03-17	Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf
DK10184491.8T DK2283834T3 (da)	1997-03-17	1998-03-17	Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10184491.8T DK2283834T3 (da)	1997-03-17	1998-03-17	Terapeutiske sammensætninger omfattende ketonforbindelser og forstadier deraf

Country Status (11)

Country	Link
EP (2)	EP2283834B1 (da)
JP (3)	JP4740426B2 (da)
KR (1)	KR100839689B1 (da)
CN (2)	CN1315473C (da)
AU (2)	AU749638B2 (da)
CA (1)	CA2283642C (da)
DK (2)	DK1017379T3 (da)
ES (1)	ES2530753T3 (da)
RU (1)	RU2224510C2 (da)
WO (2)	WO1998041200A1 (da)
ZA (1)	ZA982253B (da)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6323237B1 (en)	1997-03-17	2001-11-27	Btg International Limited	Therapeutic compositions
US6316038B1 (en)	1997-03-17	2001-11-13	Btg International Limited	Therapeutic compositions
US6380244B2 (en)	1998-07-22	2002-04-30	Metabolix, Inc.	Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers
DK1123094T3 (da) *	1998-09-15	2007-08-20	Btg Int Ltd	Terapeutiske præparater (II)
US6835750B1 (en)	2000-05-01	2004-12-28	Accera, Inc.	Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
PT1292294E (pt) *	2000-05-01	2009-06-01	Accera Inc	Utilização de triglicéridos de cadeia média para tratamento e prevenção da doença de alzheimer
ES2383673T3 (es) *	2000-09-22	2012-06-25	Jpi Commercial, Llc	Composiciones de gamma-hidroxibutirato que contienen portadores de hidrato de carbonos
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004245567B2 (en) *	2003-06-03	2011-06-23	Oxford University Innovation Limited	Nutritional supplements and therapeutic compositions comprising (R)-3-hydroxybutyrate derivatives
NZ545268A (en) *	2003-08-20	2009-05-31	Wellstat Therapeutics Corp	Compounds for the treatment of metabolic disorders
WO2005021013A1 (ja) *	2003-09-01	2005-03-10	Earthus, Inc.	β−ヒドロキシ短〜中鎖脂肪酸重合体
GB0410266D0 (en) *	2004-05-07	2004-06-09	Ketocytonyx Inc	Treatment of apoptosis
GB0420856D0 (en) *	2004-09-20	2004-10-20	Ketocytonyx Inc	Cns modulators
WO2006020179A2 (en)	2004-07-20	2006-02-23	Ketocytonyx Inc.	Oligomeric ketone compounds
US20060252775A1 (en) *	2005-05-03	2006-11-09	Henderson Samuel T	Methods for reducing levels of disease associated proteins
WO2007001883A2 (en)	2005-06-20	2007-01-04	Accera, Inc.	Method to reduce oxidative damage and improve mitochondrial efficiency
PT1976877E (pt)	2005-11-30	2014-04-29	Abbvie Inc	Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
BRPI0619905A2 (pt) *	2005-12-15	2011-10-25	Nestec Sa	composições e métodos para conservar função cerebral
PT2500017T (pt)	2006-04-03	2017-11-14	Accera Inc	Utilização de compostos cetogénicos para tratamento de comprometimento da memória associado à idade
JP5030553B2 (ja) *	2006-11-24	2012-09-19	有限会社ノーベル医学研究所	ドライマウスおよび／または唾液分泌障害を処置するための医薬
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en)	2007-02-27	2009-12-02	Abbott GmbH & Co. KG	Method for the treatment of amyloidoses
JP5504534B2 (ja) *	2007-03-30	2014-05-28	有限会社アーザス	ケトン体生成促進剤組成物
RU2459624C2 (ru)	2007-04-12	2012-08-27	Риджентс Оф Дзе Юниверсити Оф Миннесота	Защитные композиции от ишемии/реперфузии и способы применения
CA3078084C (en)	2007-07-31	2023-08-15	Cerecin Inc.	Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
EP2240017B1 (en)	2008-01-04	2019-03-13	Oxford University Innovation Limited	Ketone bodies and ketone body esters as blood lipid lowering agents
JP5630750B2 (ja) *	2008-03-18	2014-11-26	国立大学法人岡山大学	興奮性化学伝達調節剤およびそのスクリーニング法
WO2010003114A1 (en)	2008-07-03	2010-01-07	Neuera Pharmaceuticals, Inc.	Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8105809B2 (en)	2008-07-03	2012-01-31	Accera, Inc.	Enzymatic synthesis of acetoacetate esters and derivatives
US8642654B2 (en)	2009-04-16	2014-02-04	Isis Innovation Limited	Hydroxybutyrate ester and medical use thereof
CA2750510A1 (en)	2009-01-24	2010-07-29	Phytopharm Plc	Treatment of neurotrophic factor mediated disorders
DK2421808T3 (da)	2009-04-23	2013-11-04	Concert Pharmaceuticals Inc	4-Hydroxysmørsyreanaloger
CA2779282C (en) *	2009-10-22	2017-12-05	University Of Southern California	Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
GB201002983D0 (en)	2010-02-22	2010-04-07	Tdeltas Ltd	Nutritinal composition
EP2558494B1 (en)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta binding proteins
JP2013543482A (ja)	2010-07-20	2013-12-05	ファイトファームピーエルシー	Ｌ−ドーパ、ドーパミン作動薬及び／又はドーパミン賦活剤により誘発される疾患の処置
CN105348387B (zh)	2010-08-14	2020-08-25	Abbvie 公司	β淀粉样蛋白结合蛋白
KR101976218B1 (ko) *	2011-02-14	2019-05-07	콘서트 파마슈티컬즈, 인크.	4-히드록시부티르산 중수소화 유사체
WO2013007003A1 (zh) *	2011-07-08	2013-01-17	中国医学科学院基础医学研究所	乙酰乙酸调节骨骼肌细胞增殖的新用途
JP6883384B2 (ja)	2012-11-05	2021-06-09	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	電離放射線による傷害から組織を防護するためのケトン体
GB201304467D0 (en)	2013-03-12	2013-04-24	Tdeltas Ltd	Compound for use in protecting skin
SG11201507685UA (en)	2013-03-14	2015-10-29	Isis Innovation	Process for producing (r)-3-hydroxybutyl (r)-3-hydroxybutyrate
MY180761A (en)	2013-03-19	2020-12-08	Univ South Florida	Compositions and methods for producing elevated and sustained ketosis
DE102013012494A1 (de) *	2013-07-26	2015-01-29	Irma Baumeister	Verwendung von ß-Hydroxybuttersäure und Acetessigsäure sowie ihrer Salze (ß-Hydroxybutyrat und Acetacetat) als Mittel zur Behandlung bei erworbener Hypoglycorrhachie in Folge von Meningitis, Encephalitis oder Blutung in die Liquorräume
GB201314127D0 (en) *	2013-08-07	2013-09-18	Tdeltas Ltd	Ketone body and ketone body ester for reducing muscle breakdown
EP3177284B1 (en)	2014-07-21	2020-01-15	Oulun Yliopisto	Oligomeric forms of 3-hydroxybutyrate
US10736861B2 (en)	2016-03-11	2020-08-11	Axcess Global Sciences, Llc	Mixed salt compositions for producing elevated and sustained ketosis
US11103470B2 (en)	2017-11-22	2021-08-31	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596130B2 (en)	2017-12-19	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10973792B2 (en)	2019-02-13	2021-04-13	Axcess Global Sciences, Llc	Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596131B2 (en)	2017-11-22	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en)	2017-12-19	2019-04-02	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US10596129B2 (en)	2017-11-22	2020-03-24	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en)	2016-03-11	2021-04-13	Axcess Global Sciences, Llc	R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10245242B1 (en)	2017-11-22	2019-04-02	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11185518B2 (en)	2017-12-19	2021-11-30	Axcess Global Sciences, Llc	S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en)	2016-03-11	2022-02-08	Axcess Global Sciences, Llc	Beta-hydroxybutyrate mixed salt compositions and methods of use
US11944598B2 (en)	2017-12-19	2024-04-02	Axcess Global Sciences, Llc	Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12622889B2 (en)	2016-04-19	2026-05-12	Axcess Global Sciences, Llc	S-β-hydroxybutyrate esters for improving metabolic function
US12533346B2 (en)	2016-04-19	2026-01-27	Axcess Global Sciences, Llc	Administration of berberine metabolites
US11806324B2 (en)	2018-04-18	2023-11-07	Axcess Global Sciences, Llc	Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12599579B2 (en)	2016-04-19	2026-04-14	Axcess Global Sciences, Llc	Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US10925843B2 (en)	2018-04-18	2021-02-23	Axcess Global Sciences, Llc	Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US12521378B2 (en)	2016-04-19	2026-01-13	Axcess Global Sciences, Llc	Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US12109182B2 (en)	2016-04-19	2024-10-08	Axcess Global Sciences, Llc	Administration of R-beta-hydroxybutyrate and related compounds in humans
US20230346721A1 (en)	2018-04-18	2023-11-02	Axcess Global Sciences, Llc	Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US11202769B2 (en)	2017-11-22	2021-12-21	Axcess Global Sciences, Llc	Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12329734B2 (en)	2017-12-19	2025-06-17	Axcess Global Sciences, Llc	Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12496283B2 (en)	2016-04-19	2025-12-16	Axcess Global Sciences, Llc	Administration of R-beta-hydroxybutyrate and related compounds in humans
JP6710098B2 (ja) *	2016-05-10	2020-06-17	大阪瓦斯株式会社	栄養剤組成物及び栄養補助食品
MX2021009806A (es) *	2016-06-07	2022-11-30	The J David Gladstone Inst	Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
US10307398B2 (en)	2016-09-20	2019-06-04	Regents Of The University Of Minnesota	Resuscitation composition and methods of making and using
CA3046415A1 (en)	2016-12-21	2018-06-28	Universitats-Kinderspital Beider Basel	Migraine prevention and treatment
US9925164B1 (en)	2017-01-12	2018-03-27	Neuroenergy Ventures, Inc.	Glyceryl 3-hydroxybutyrates for traumatic brain injury
WO2018187852A1 (en) *	2017-04-12	2018-10-18	Cavaleri Franco	Butyrate and beta-hydroxybutyrate compositions and methods of use thereof
GB201710229D0 (en)	2017-06-27	2017-08-09	Tdeltas Ltd	Compounds for new use
AU2018304380B2 (en)	2017-07-21	2022-12-15	Buck Institute For Research On Aging	S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same
WO2019035486A1 (ja) *	2017-08-18	2019-02-21	拓己佐藤	血糖値スパイク抑制剤、食品及び血糖値スパイク抑制剤の製造方法
US12090129B2 (en)	2017-11-22	2024-09-17	Axcess Global Sciences, Llc	Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
WO2019147503A1 (en)	2018-01-25	2019-08-01	Buck Institute For Research On Aging	Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
US11129802B2 (en)	2018-08-27	2021-09-28	Axcess Global Sciences, Llc	Compositions and methods for delivering cannabidiol and ketone bodies
US10980772B2 (en)	2018-08-27	2021-04-20	Axcess Global Sciences, Llc	Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11419836B2 (en)	2019-02-13	2022-08-23	Axcess Global Sciences, Llc	Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10512615B1 (en)	2018-08-27	2019-12-24	Axcess Global Sciences, Llc	Compositions and methods for delivering cannabidiol and ketone bodies
US11241401B2 (en)	2020-02-06	2022-02-08	Axcess Global Sciences, Llc	Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
CN112367987A (zh) *	2018-06-05	2021-02-12	旗舰创业创新五公司	活性剂和其用于治疗代谢障碍和非酒精性脂肪性肝病的方法
IT201800007524A1 (it) *	2018-07-26	2020-01-26	Bio-On Spa	Poliidrossialcanoati per l'uso nella prevenzione o nel trattamento di una condizione di sovrappeso o di obesita', ovvero di disfunzioni metaboliche correlate a tale condizione.
EP3965740A1 (en) *	2019-05-10	2022-03-16	KetoSwiss AG	Ketone bodies enclosed in microbeads
US12472200B2 (en)	2019-05-15	2025-11-18	Axcess Global Sciences, Llc	Autobiotic compositions and method for promoting healthy gut microbiome
EP3975754A1 (en) *	2019-05-28	2022-04-06	Mayo Foundation for Medical Education and Research	Nutritional health supplements
KR20220016145A (ko)	2019-05-30	2022-02-08	뉴로에너지 벤처스 인코포레이티드	글리세릴 트리스(베타-하이드록시부티레이트) 및 신경 일과성 허혈 발작
WO2020249198A1 (de) *	2019-06-12	2020-12-17	Ioi Oleo Gmbh	Verfahren zur herstellung von polyolbasierten estern von acylverkappten 3-hydroxycarbonsäuren
US12570599B2 (en) *	2019-06-12	2026-03-10	Ketolipix Therapeutics Gmbh	Process for preparing acyl-capped 3-hydroxycarboxylic acids and their salts and esters
US11969430B1 (en)	2023-03-10	2024-04-30	Axcess Global Sciences, Llc	Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12167993B2 (en)	2019-06-21	2024-12-17	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11033553B2 (en)	2019-06-21	2021-06-15	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en)	2019-06-21	2024-04-09	Axcess Global Sciences, Llc	Non-vasoconstricting energy-promoting compositions containing ketone bodies
CN110776425B (zh) *	2019-10-23	2021-02-26	清华大学	一种(r)-3-羟基丁酸及其低聚物的制备方法
JP7507580B2 (ja) *	2020-03-25	2024-06-28	大阪瓦斯株式会社	醸造酢代替物の製造方法、醸造酢代替物および醸造酢代替物含有食品
WO2021195477A1 (en)	2020-03-27	2021-09-30	Ketoneaid, Inc.	Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
JP2021185799A (ja) *	2020-05-28	2021-12-13	大阪瓦斯株式会社	３−ヒドロキシ酪酸含有油脂組成物
US12186297B2 (en)	2020-08-26	2025-01-07	Axcess Global Sciences, Llc	Compositions and methods for increasing lean-to-fat mass ratio
CN113200849B (zh) *	2021-04-27	2025-07-18	香港理工大学	合成的3-羟基丁酸酯低聚物或寡聚物的分离纯化方法及其在抗菌抗病毒制品中的应用
WO2022254764A1 (ja) *	2021-06-01	2022-12-08	大阪瓦斯株式会社	３－ヒドロキシ酪酸含有油脂組成物
CN113866399A (zh) *	2021-11-03	2021-12-31	上海交通大学医学院附属仁济医院	肝脏酮体在急性胰腺炎病情监测和治疗上的应用
US20250008999A1 (en) *	2021-11-04	2025-01-09	Vdf Futureceuticals, Inc.	Ketone Precursors And Methods Therefor
CN117243939B (zh) *	2023-11-14	2025-03-07	南京今冉生物新材料科技有限公司	一种酮体缓释物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1912406A1 (de) *	1969-03-12	1970-10-01	Basf Ag	Verfahren zur Herstellung von Acetessigsaeureestern
CH626651A5 (da) *	1976-08-06	1981-11-30	Agroferm Ag
JPS54138126A (en) *	1978-04-17	1979-10-26	Ajinomoto Co Inc	Remedy for diabetes
US4346107A (en) *	1979-02-12	1982-08-24	Claudio Cavazza	Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) *	1979-02-12	1989-05-17	Sigma Tau Ind Farmaceuti	Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
DE2930405C2 (de) *	1979-07-26	1982-09-23	Optische Werke G. Rodenstock, 8000 München	Stimulus-Leuchte für augenoptische Untersuchungsgertäte
FR2521857B1 (fr) *	1982-02-23	1985-10-31	Solvay	Compositions pharmaceutiques contenant de l'acide 3-hydroxybutanoique ou un sel derive de cet acide et sels derives de l'acide 3-hydroxybutanoique et d'une base organique azotee
GB2126082A (en) *	1982-08-12	1984-03-21	Heinrich Schulze	Pharmaceutical preparations having analgetic and cytostatic activity
US5719119A (en) *	1985-12-18	1998-02-17	British Technology Group, Ltd.	Parenteral nutrition therapy with amino acids
EP0250559A1 (en) *	1985-12-18	1988-01-07	VEECH, Richard L.	Parenteral nutrition therapy with amino acids
US5126373A (en) *	1987-11-19	1992-06-30	Henri Brunengraber	Composition for parenteral and oral nutrition
BE1001209A3 (fr) *	1987-11-19	1989-08-22	Solvay	Compositions pharmaceutiques contenant un derive de l'acide 3-hydroxybutanoique choisi parmi les oligomeres de cet acide et les esters de cet acide ou de ces oligomeres avec du 1,3-butanediol.
CA1334575C (en) *	1988-07-26	1995-02-28	Atsushi Hiraide	Substitution fluid preparation comprising 3-hydroxybutyric acid (beta-hydroxybutyric acid) and its salts
US5116868A (en) *	1989-05-03	1992-05-26	The Johns Hopkins University	Effective ophthalmic irrigation solution
IT1240775B (it) *	1990-02-23	1993-12-17	Sigma Tau Ind Farmaceuti	Esteri della l-carnitina e di acil-l-carnitine con l'acido beta-idrossibutirrico e composizioni farmaceutiche che li contengono per la inibizione della degenerazione neuronale, della proteolisi epatica e nel trattamento del coma.
JPH0733653A (ja) *	1993-06-25	1995-02-03	Suntory Ltd	アセトアルデヒド毒性の抑制剤
WO1995009145A1 (en) *	1993-09-30	1995-04-06	Eastman Chemical Company	NUTRITIVE GLYCEROL ESTERS OF β-ACYLOXY BUTYRATES
JP4598203B2 (ja)	1995-12-01	2010-12-15	ビーティージー・インターナショナル・リミテッド	脳機能改善剤
JPH10120553A (ja) *	1996-10-23	1998-05-12	Eisai Co Ltd	抗痴呆薬含有製剤

1998
- 1998-03-17 DK DK98911664.5T patent/DK1017379T3/da active
- 1998-03-17 WO PCT/IB1998/000516 patent/WO1998041200A1/en not_active Ceased
- 1998-03-17 ES ES98911664T patent/ES2530753T3/es not_active Expired - Lifetime
- 1998-03-17 CN CNB98805163XA patent/CN1315473C/zh not_active Expired - Lifetime
- 1998-03-17 EP EP10184491.8A patent/EP2283834B1/en not_active Expired - Lifetime
- 1998-03-17 AU AU65569/98A patent/AU749638B2/en not_active Expired
- 1998-03-17 ZA ZA9802253A patent/ZA982253B/xx unknown
- 1998-03-17 AU AU65132/98A patent/AU6513298A/en not_active Abandoned
- 1998-03-17 DK DK10184491.8T patent/DK2283834T3/da active
- 1998-03-17 RU RU99121849/15A patent/RU2224510C2/ru not_active IP Right Cessation
- 1998-03-17 EP EP98911664.5A patent/EP1017379B1/en not_active Expired - Lifetime
- 1998-03-17 JP JP54065698A patent/JP4740426B2/ja not_active Expired - Fee Related
- 1998-03-17 WO PCT/US1998/005072 patent/WO1998041201A1/en not_active Ceased
- 1998-03-17 KR KR1019997008481A patent/KR100839689B1/ko not_active Expired - Fee Related
- 1998-03-17 CA CA2283642A patent/CA2283642C/en not_active Expired - Lifetime
- 1998-03-17 CN CN2004100473586A patent/CN1552315B/zh not_active Expired - Lifetime
2009
- 2009-04-28 JP JP2009109987A patent/JP5800453B2/ja not_active Expired - Lifetime
2014
- 2014-09-25 JP JP2014194771A patent/JP2015042644A/ja active Pending

Also Published As

Publication number	Publication date
ES2530753T3 (es)	2015-03-05
CN1552315B (zh)	2010-11-10
JP2009173677A (ja)	2009-08-06
AU749638B2 (en)	2002-06-27
KR100839689B1 (ko)	2008-06-18
CN1315473C (zh)	2007-05-16
EP2283834A3 (en)	2012-02-01
JP2015042644A (ja)	2015-03-05
KR20000076379A (ko)	2000-12-26
RU2224510C2 (ru)	2004-02-27
ZA982253B (en)	1999-09-17
CA2283642A1 (en)	1998-09-24
EP1017379B1 (en)	2014-12-10
CN1256629A (zh)	2000-06-14
JP2001515510A (ja)	2001-09-18
JP4740426B2 (ja)	2011-08-03
AU6556998A (en)	1998-10-12
CN1552315A (zh)	2004-12-08
WO1998041200A1 (en)	1998-09-24
JP5800453B2 (ja)	2015-10-28
AU6513298A (en)	1998-10-12
DK2283834T3 (da)	2016-08-15
EP2283834A2 (en)	2011-02-16
CA2283642C (en)	2012-05-15
EP1017379A1 (en)	2000-07-12
EP1017379A4 (en)	2007-01-24
WO1998041201A1 (en)	1998-09-24
EP2283834B1 (en)	2016-07-13

Publication	Publication Date	Title
EP1017379B1 (en)	2014-12-10	Therapeutic compositions comprising ketone bodies and precursors thereof
US6316038B1 (en)	2001-11-13	Therapeutic compositions
US6207856B1 (en)	2001-03-27	Therapeutic compositions
US20180098956A1 (en)	2018-04-12	Therapeutic compositions
EP1123094B1 (en)	2007-04-11	Therapeutic compositions (ii)
WO1998041201A9 (en)	1999-03-11	Therapeutic compositions
HK1035665B (en)	2007-06-15	Therapeutic compositions (ii)
MXPA01002672A (en)	2001-12-04	Therapeutic compositions (ii)